Longbio Pharma

Suzhou, China · Founded 2020 · In IPO Registration

Manufacturer of antibody-based biologics intended for autoimmune and allergic diseases. Longbio Pharma is based in Suzhou, China and was founded in 2020. Its last reported valuation was $278 million in May 2025. It has raised $76.7 million.

Last reported valuation

$277.8M

Oct 2026

Priced at

—

Total raised

$76.7M

Last round

—

How much has Longbio Pharma raised?

$76.7Macross 0 recorded rounds

Free account

More of Longbio Pharma with a free account

·The complete investor list: 13 names
·Watch Longbio Pharma: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Longbio Pharma investors

13 investors are on record for Longbio Pharma, including Qiming Venture Partners, Oriental Fortune Capital, Highlight Capital and Shanghai Lingang Economic Development.

For fundraisers

Raising for a company like Longbio Pharma?

13 investors have backed Longbio Pharma.

See all 13 investors →

Frequently asked about Longbio Pharma

How much has Longbio Pharma raised?: Longbio Pharma has raised $76.7M in total across 0 recorded funding rounds.